Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

NCT03502733 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03502733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03502733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 14, 2018
Completion date
August 1, 2027
Enrollment
64 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, metastatic malignant solid neoplasm, recurrent malignant solid neoplasm, unresectable malignant solid neoplasm